1099.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 16:08):

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China...

Stats
今日成交量	18.07M
平均成交量	5.10M
市值	63.00B
EPS	HKD0 ( 2024-04-25 )
Last Dividend	HKD0.901 ( 2023-06-19 )
Next Dividend	HKD0 ( N/A )
P/E	6.45
ATR14	HKD0.0460 (0.23%)

音量相关性

長: 0.09 (neutral)

短: -0.43 (neutral)

Signal:(45.299) Neutral

SINOPHARM GROUP CO LTD 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

SINOPHARM GROUP CO LTD 相关性 - 货币/商品

-0.04
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.29
( neutral )

-0.65
( moderate negative )

0.05
( neutral )

SINOPHARM GROUP CO LTD 财务报表

Annual	2023
营收:	HKD596.57B
毛利润:	HKD48.51B (8.13 %)
EPS:	HKD2.90

FY	2023
营收:	HKD596.57B
毛利润:	HKD48.51B (8.13 %)
EPS:	HKD2.90

FY	2022
营收:	HKD552.15B
毛利润:	HKD47.43B (8.59 %)
EPS:	HKD4.60

FY	2021
营收:	HKD521.05B
毛利润:	HKD44.05B (8.45 %)
EPS:	HKD2.49

Financial Reports:

No articles found.

SINOPHARM GROUP CO LTD Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.901 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

SINOPHARM GROUP CO LTD Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.69 - good (96.91%) | Divividend Growth Potential Score: 3.37 - Decrease likely (32.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0101	2010-04-29
Last Dividend	HKD0.901	2023-06-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	14	--
Total Paid Out	HKD6.94	--
Avg. Dividend % Per Year	0.00%	--
Score	2.6	--
Div. Sustainability Score	9.69
Div.Growth Potential Score	3.37
Div. Directional Score	6.53	--

Next Divdend (Est)
(2025-04-07)

HKD0.958 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2359.HK	Ex Dividend Knight	2023-06-05	Annually	0.00%
1345.HK	Ex Dividend Junior	2023-10-04	Semi-Annually	0.00%
0390.HK	Ex Dividend Junior	2023-07-19	Annually	0.00%
6626.HK	Ex Dividend Knight	2023-09-04	Annually	0.00%
1897.HK	Ex Dividend Knight	2023-07-05	Semi-Annually	0.00%
0921.HK	Ex Dividend Junior	2023-07-10	Sporadic	0.00%
0052.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
2869.HK	Ex Dividend Junior	2023-06-20	Annually	0.00%
1469.HK	Ex Dividend Knight	2023-08-29	Semi-Annually	0.00%
0546.HK	Ex Dividend Knight	2023-09-18	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0155	1.500	9.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0358	1.200	8.81	10.00	[0 - 0.3]
returnOnEquityTTM	0.194	1.500	8.96	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.395	0.800	8.03	6.42	[1 - 3]
quickRatioTTM	1.034	0.800	8.63	6.90	[0.8 - 2.5]
cashRatioTTM	0.264	1.500	9.64	10.00	[0.2 - 2]
debtRatioTTM	0.188	-1.500	6.87	-10.00	[0 - 0.6]
interestCoverageTTM	20.69	1.000	3.45	3.45	[3 - 30]
operatingCashFlowPerShareTTM	23.49	2.00	2.17	4.34	[0 - 30]
freeCashFlowPerShareTTM	22.23	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.965	-1.500	6.14	-9.21	[0 - 2.5]
grossProfitMarginTTM	0.0838	1.000	-1.937	-1.937	[0.2 - 0.8]
operatingProfitMarginTTM	0.0381	1.000	-1.238	-1.238	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.017	1.000	5.46	5.46	[0.2 - 2]
assetTurnoverTTM	2.31	0.800	10.00	8.00	[0.5 - 2]
Total Score				9.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.31	1.000	9.67	0	[1 - 100]
returnOnEquityTTM	0.194	2.50	9.33	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	22.23	2.00	2.59	10.00	[0 - 30]
dividendYielPercentageTTM	4.75	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	23.49	2.00	2.17	4.34	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0825	1.000	-0.437	0	[0.1 - 0.5]
Total Score				3.37

SINOPHARM GROUP CO LTD

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.